|
Volumn 466, Issue 7310 SUPPL., 2010, Pages
|
Treatment frontiers
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADX 48621;
ANTIPARKINSON AGENT;
DOPAMINE;
GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;
GLUTAMATE DECARBOXYLASE;
LEVODOPA;
METABOTROPIC RECEPTOR 5;
NEURTURIN;
UNCLASSIFIED DRUG;
BRAIN;
DISEASE TREATMENT;
DRUG;
ELECTRODE;
NERVOUS SYSTEM DISORDER;
ADRENAL GLAND;
BASAL GANGLION;
BLOOD BRAIN BARRIER;
BRAIN DEPTH STIMULATION;
BRAIN REGION;
CELL THERAPY;
CLINICAL TRIAL;
CONFUSION;
DEPRESSION;
DISEASE COURSE;
DOPAMINERGIC NERVE CELL;
DOPAMINERGIC SYSTEM;
DYSKINESIA;
ELECTROSTIMULATION;
EMBRYONIC STEM CELL;
GENE THERAPY;
GLOBUS PALLIDUS;
HUMAN;
MIGRAINE;
NAUSEA;
PARKINSON DISEASE;
PREMOTOR CORTEX;
PRIORITY JOURNAL;
REVIEW;
STEM CELL TRANSPLANTATION;
SUBSTANTIA NIGRA;
SUBTHALAMIC NUCLEUS;
TRANSCRANIAL MAGNETIC STIMULATION;
UNIFIED PARKINSON DISEASE RATING SCALE;
ANTIPARKINSON AGENTS;
DEEP BRAIN STIMULATION;
HUMANS;
LEVODOPA;
PARKINSON DISEASE;
RECEPTORS, ADENOSINE A2;
RESEARCH;
TISSUE THERAPY;
|
EID: 77956212276
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/466S15a Document Type: Review |
Times cited : (11)
|
References (17)
|